Alantolactone selectively ablates acute myeloid leukemia stem and progenitor cells

Abstract Background The poor outcomes for patients diagnosed with acute myeloid leukemia (AML) are largely attributed to leukemia stem cells (LSCs) which are difficult to eliminate with conventional therapy and responsible for relapse. Thus, new therapeutic strategies which could selectively target...

Full description

Bibliographic Details
Main Authors: Yahui Ding, Huier Gao, Yu Zhang, Ye Li, Neil Vasdev, Yingdai Gao, Yue Chen, Quan Zhang
Format: Article
Language:English
Published: BMC 2016-09-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13045-016-0327-5